Opus Genetics (IRD) Payables (2010 - 2026)
Opus Genetics (IRD) reported Payables of $4.4 million for Q1 2026, up 81.98% year-over-year from $2.4 million in Q1 2025, and up 34.28% on a QoQ basis from $3.3 million in Q4 2025.
Opus Genetics (IRD) has 17 years of Payables data on file, last reported at $4.4 million in Q1 2026.
- Quarterly Payables rose 81.98% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 81.98% YoY) and the FY2025 annual result came in at $3.3 million, up 4.61% from the prior year.
- Payables grew to $4.4 million in Q1 2026 per IRD's latest filing, from $3.3 million in the prior quarter.
- Across five years, Payables topped out at $4.4 million in Q1 2026 and bottomed at $634000.0 in Q2 2024.
- The 5-year median for Payables is $2.1 million (2024), against an average of $2.1 million.
- The widest annual swing landed in 2024, when Payables sank 72.71%; it then surged 183.77% in 2025.
- Tracing IRD's Payables over 5 years: stood at $1.1 million in 2022, then surged by 101.4% to $2.2 million in 2023, then jumped by 46.21% to $3.1 million in 2024, then grew by 4.61% to $3.3 million in 2025, then jumped by 34.28% to $4.4 million in 2026.
- Per Business Quant, the three latest IRD Payables figures stand at $4.4 million (Q1 2026), $3.3 million (Q4 2025), and $2.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | 4.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.42 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 2.40 Mn |
| Jun 30, 2025 | 1.47 Mn |
| Mar 31, 2025 | 2.43 Mn |
| Dec 31, 2024 | 3.15 Mn |
| Sep 30, 2024 | 844,000.00 |
| Jun 30, 2024 | 634,000.00 |
| Mar 31, 2024 | 2.06 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 1.89 Mn |
| Jun 30, 2023 | 2.32 Mn |
| Mar 31, 2023 | 2.22 Mn |
| Dec 31, 2022 | 1.07 Mn |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 1.89 Mn |
| Mar 31, 2022 | 1.79 Mn |
| Dec 31, 2021 | 2.12 Mn |
| Sep 30, 2021 | 1.43 Mn |
| Jun 30, 2021 | 1.50 Mn |
| Mar 31, 2021 | 1.42 Mn |
| Dec 31, 2020 | 1.21 Mn |
| Sep 30, 2020 | 2.26 Mn |
| Jun 30, 2020 | 2.19 Mn |
| Mar 31, 2020 | 1.24 Mn |
| Dec 31, 2019 | 5.32 Mn |
| Sep 30, 2019 | 1.37 Mn |
| Jun 30, 2019 | 1.92 Mn |
| Mar 31, 2019 | 2.25 Mn |
| Dec 31, 2018 | 3.15 Mn |
| Sep 30, 2018 | 3.33 Mn |
| Jun 30, 2018 | 3.38 Mn |
| Mar 31, 2018 | 3.05 Mn |
| Dec 31, 2017 | 3.23 Mn |
| Sep 30, 2017 | 2.34 Mn |
| Jun 30, 2017 | 1.92 Mn |
| Mar 31, 2017 | 1.72 Mn |
| Dec 31, 2016 | 1.88 Mn |
| Sep 30, 2016 | 1.79 Mn |
| Jun 30, 2016 | 1.79 Mn |
| Mar 31, 2016 | 3.28 Mn |
| Dec 31, 2015 | 2.66 Mn |
| Sep 30, 2015 | 3.24 Mn |
| Jun 30, 2015 | 3.17 Mn |
| Mar 31, 2015 | 2.75 Mn |
| Dec 31, 2014 | 2.46 Mn |
| Sep 30, 2014 | 1.73 Mn |
| Jun 30, 2014 | 1.54 Mn |
| Mar 31, 2014 | 878,500.00 |
| Dec 31, 2013 | 933,758.00 |
| Sep 30, 2013 | 750,242.00 |
| Jun 30, 2013 | 620,067.00 |
| Mar 31, 2013 | 976,166.00 |
| Dec 31, 2012 | 851,837.00 |
| Sep 30, 2012 | 871,507.00 |
| Jun 30, 2012 | 890,967.00 |
| Mar 31, 2012 | 1.02 Mn |
| Dec 31, 2011 | 1.19 Mn |
| Sep 30, 2011 | 3.91 Mn |
| Jun 30, 2011 | 3.89 Mn |
| Dec 31, 2010 | 1.82 Mn |